A significant number of medicinal products, despite their long tradition, do not fulfil the requirements of a well-established medicinal use with recognised efficacy and an acceptable level of safety and are not eligible for a marketing authorisation. To maintain these products on the market, the Member States have enacted differing procedures and provisions. The differences that currently exist between the provisions laid down in the Member States may hinder trade in traditional medicinal products within the Community and lead to discrimination and distortion of competition between manufacturers of these products. They may also have an impact on the protection of public health since the necessary guarantees of quality, safety and efficacy are not always provided at present.
Recital 3, Directive (EU) 2004/24
In forcesince 31 Mar 2004cited 1×
Opinion of Mr Advocate General Bot delivered on 24 May 2007. Staat der Nederlanden v Antroposana, Patiëntenvereniging voor Antroposofische GDecision
The introduction of that procedure was justified by the Community legislature as follows in the third recital in the preamble to Directive 2004/24:‘[a] significant number of medicinal products, despite their long tradition, do not fulfil …
24 May 2007 · 62006CC0084